Patrick Murray
YOU?
Author Swipe
View article: Urine Tubular Biomarkers Are Associated With Natriuresis in Patients With Acute Heart Failure
Urine Tubular Biomarkers Are Associated With Natriuresis in Patients With Acute Heart Failure Open
Background Loop diuretics require functioning kidney tubules to increase the excretion of sodium into urine thereby relieving congestion in patients with acute heart failure ( AHF ). Whether biomarkers of kidney tubular health are associat…
View article: Albuminuria is associated with worse outcomes in non‐diabetics hospitalized with acute heart failure
Albuminuria is associated with worse outcomes in non‐diabetics hospitalized with acute heart failure Open
Aims Chronic kidney disease (CKD) increases the risk of morbidity and mortality in patients with heart failure (HF). Guidelines recommend assessing CKD using the urinary albumin‐to‐creatinine ratio (UACR), as albuminuria is strongly associ…
View article: #3385 The short and long-term accuracy of urinary C-C motif Chemokine-14 in an ICU population
#3385 The short and long-term accuracy of urinary C-C motif Chemokine-14 in an ICU population Open
Background and Aims Acute Kidney Injury (AKI) is a life-threatening syndrome associated with significant short- and long-term negative outcomes. Current AKI clinical biomarkers, such as serum creatinine and urine output, are limited. The D…
View article: Brain tissue oxygen monitoring for severe traumatic brain injury: the international multicentre randomised controlled BONANZA-GT study protocol
Brain tissue oxygen monitoring for severe traumatic brain injury: the international multicentre randomised controlled BONANZA-GT study protocol Open
Introduction The management of severe traumatic brain injury (sTBI) in the intensive care unit (ICU) is focused on preventing secondary brain insults, by ensuring adequate cerebral perfusion, oxygenation and substrate delivery. Despite opt…
View article: #535 Audit of the clinical implementation of urinary NGAL in the diagnostic work-up of acute kidney injury at an Irish Hospital
#535 Audit of the clinical implementation of urinary NGAL in the diagnostic work-up of acute kidney injury at an Irish Hospital Open
Background and Aims Differentiating functional acute kidney injury (AKI) from structural tubular injury AKI remains challenging with existing clinical tools. urinary NGAL (uNGAL) has shown promise in distinguishing functional AKI, such as …
View article: Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure
Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure Open
Background Kidney dysfunction, defined by measures of glomerular health, in patients hospitalized with acute heart failure (HF) is associated with death and HF readmission. We aimed to determine if kidney tubule damage and dysfunction are …
View article: Clinical Implementation of Urinary Neutrophil Gelatinase-Associated Lipocalin Testing for Diagnosing Acute Kidney Injury in an Academic Tertiary Care Medical Centre
Clinical Implementation of Urinary Neutrophil Gelatinase-Associated Lipocalin Testing for Diagnosing Acute Kidney Injury in an Academic Tertiary Care Medical Centre Open
Key Points Urinary neutrophil gelatinase-associated lipocalin is a sensitive urinary biomarker in the differentiation of intrinsic (intrarenal) AKI from nonintrinsic (prerenal and postrenal) AKI. Urinary neutrophil gelatinase-associated li…
View article: Transition From Intraoperative Vancomycin‐Piperacillin Tazobactam to Vancomycin‐Cefepime Does Not Change Acute Kidney Injury or Renal Recovery Outcomes in Patients Undergoing Heart Transplantation
Transition From Intraoperative Vancomycin‐Piperacillin Tazobactam to Vancomycin‐Cefepime Does Not Change Acute Kidney Injury or Renal Recovery Outcomes in Patients Undergoing Heart Transplantation Open
Introduction The impact of empiric intraoperative vancomycin and piperacillin‐tazobactam (VPT) compared to vancomycin and cefepime (VC) on AKI is equivocal, and renal recovery and infection outcomes have not been studied in this context. F…
View article: Inhibition of Calcium Release-Activated Calcium (CRAC) channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE study
Inhibition of Calcium Release-Activated Calcium (CRAC) channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE study Open
Introduction: Patients with severe acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) experience poorer outcomes, including higher rates of in-hospital mortality, relative to patients with less severe AKI,…
View article: A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS) Open
Background Cardiac procedures, particularly those requiring cardiopulmonary bypass (CPB), are associated with the development of cardiac surgery-associated acute kidney injury (CSA-AKI). Development of CSA-AKI occurs as a result of inflamm…
View article: Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers
Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers Open
NBMs accurately and timely detected cisplatin exposure and identified "sub-clinical" DIKI undetected by standard acute kidney injury (AKI) criteria, highlighting the limitations of current functional BMs in estimating the true DIKI inciden…
View article: Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury Open
BACKGROUND: Worsening renal function (WRF) is common in hospitalized patients being treated for acute heart failure. However, discriminating clinically significant WRF remains challenging. In patients hospitalized with acute heart failure,…
View article: Significance of an Early Repeat Troponin Measurement Upon Presentation to the Hospital for Acute Heart Failure
Significance of an Early Repeat Troponin Measurement Upon Presentation to the Hospital for Acute Heart Failure Open
Background Higher cardiac troponin is associated with worse outcomes in patients with acute heart failure. The significance of repeat measurements over hours remains unclear. We assessed whether a repeat measurement and the Δ between measu…
View article: Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement
Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement Open
The current lack of specific therapy for prevention or treatment of AKI demands refinement of future clinical trial design. Here we report the consensus findings of the 31st ADQI group meeting which has attempted to address these issues in…
View article: Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup
Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup Open
Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possi…
View article: Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL) Open
After the publication of the article, we have been informed that the name of a contributor in the list of REVIVAL investigators was given incomplete. He was given as “Patrick Honore” or “Honore P” but he should have been cited as “Patrick …
View article: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL) Open
Among critically ill patients with SA-AKI, ilofotase alfa did not improve day 28 survival. There may, however, be reduced MAKE90 events. No safety concerns were identified.
View article: 47 Pulse field ablation in Irish atrial fibrillation. Patient characteristics, safety, and single operator experience from the first 50 cases
47 Pulse field ablation in Irish atrial fibrillation. Patient characteristics, safety, and single operator experience from the first 50 cases Open
Introduction Pulse Field Ablation (PFA) is an exciting novel technology in the field of Atrial Fibrillation (AF). The technology delivers high amplitude electrical pulses with tissue specificity to target myocardium. This technology offers…
View article: Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury Cases
Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury Cases Open
The identification of DI-AKI is challenging even with comprehensive adjudication by experienced nephrologists. Our analysis identified key clinical characteristics and outcomes of DI-AKI compared to other AKI etiologies.
View article: Phase 3 Trial of Recombinant Human Alkaline Phosphatase for Patients with Sepsis-Associated Acute Kidney Injury (REVIVAL)
Phase 3 Trial of Recombinant Human Alkaline Phosphatase for Patients with Sepsis-Associated Acute Kidney Injury (REVIVAL) Open
Purpose: Ilofotase alfa is a human recombinant alkaline phosphatase with reno-protective effects that showed improved survival and reduced MAKE90 in sepsis-associated acute kidney injury (SA-AKI) patients. ‘ REVIVAL’, was aphase 3 trial, c…
View article: Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury Open
Introduction Sepsis, the leading cause of acute kidney injury (AKI), is associated with a high morbidity and mortality. Alkaline phosphatase (ALP) is an endogenous detoxifying enzyme. A recombinant human ALP compound, ilofotase alfa, showe…